Patients-Lay Language Summaries Template

Lorem Ipsum Dummy Text

Cras eget euismod eros, sed suscipit mi

Cras id ante semper, pellentesque metus ac, rhoncus ex. Vestibulum in porttitor massa. Donec ornare leo erat, ac mollis ex cursus a. Nunc sodales auctor metus. Maecenas tempor neque a mi ornare fermentum. Maecenas faucibus pretium sem. Nam accumsan mollis libero. In vitae posuere diam. Vestibulum in accumsan nunc, nec fermentum ipsum. Vestibulum eget leo in mauris facilisis efficitur. Donec lobortis lacus non accumsan varius

Know More

Lorem Ipsum is a dummy Content

Pellentesque habitant morbi tristique

All
Offices

Filter

Showing: 1 – 5 of 31 stories

Show

Sort

Ipsen launches educational initiative to support teens and young adults moving from pediatric to adult healthcare

23 October 2025 • 4 mins read

23 October 2025 – 4 mins read

Ipsen launches educational initiative to support teens and young adults moving from pediatric to adult healthcare

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

18 November 2024 • 12 mins read

18 November 2024 – 12 mins read

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay® from two Phase III open-label…

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

15 November 2024 • 12 mins read

15 November 2024 – 12 mins read

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE® study at the American Association for…

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

10 June 2024 • 12 mins read

10 June 2024 – 12 mins read

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

PARIS, FRANCE, 10 June 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo® (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination…

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis

05 June 2024 • 7 mins read

05 June 2024 – 7 mins read

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis

PARIS, FRANCE, 5 June 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced new late-breaking data at the European Association for the Study of the Liver (EASL) Congress demonstrating the enduring efficacy of elafibranor in managing disease progression after 78 weeks of…

…

Clinical Trial

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Cras eget euismod eros, sed suscipit mi. Suspendisse potenti. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Pellentesque rhoncus eget justo vel suscipit